GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OSTO:MVIR) » Definitions » Degree of Operating Leverage

Medivir AB (OSTO:MVIR) Degree of Operating Leverage : -0.27 (As of Mar. 2025)


View and export this data going back to 1996. Start your Free Trial

What is Medivir AB Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Medivir AB's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was -0.27. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Medivir AB's Degree of Operating Leverage or its related term are showing as below:

OSTO:MVIR's Degree of Operating Leverage is ranked better than
60.16% of 881 companies
in the Biotechnology industry
Industry Median: -0.02 vs OSTO:MVIR: -0.27

Medivir AB Degree of Operating Leverage Historical Data

The historical data trend for Medivir AB's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Degree of Operating Leverage Chart

Medivir AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.15 0.55 -0.51 0.06 -0.73

Medivir AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 2.16 1.41 -0.73 -0.27

Competitive Comparison of Medivir AB's Degree of Operating Leverage

For the Biotechnology subindustry, Medivir AB's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivir AB's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Medivir AB's Degree of Operating Leverage falls into.


;
;

Medivir AB Degree of Operating Leverage Calculation

Medivir AB's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -113.4 (Mar. 2025) / -99.2 (Mar. 2024) - 1 )/( 3.6 (Mar. 2025) / 7.7 (Mar. 2024) - 1 )
=0.1431/-0.5325
=-0.27***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Medivir AB  (OSTO:MVIR) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Medivir AB Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Medivir AB's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Medivir AB Business Description

Industry
Traded in Other Exchanges
Address
Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also has various out-licensed projects, such as MIV-701, birinapant, USP-1/TNG348, USP-7, and MBLI/MET-X, as well as two other drug projects, remetinostat and MIV-711, in the clinical development phase. Geographically, it generates its maximum revenue from Europe and other regions.

Medivir AB Headlines

No Headlines